ZA201107551B - Compositions and methods for antibodies targeting complement protein c3b - Google Patents

Compositions and methods for antibodies targeting complement protein c3b

Info

Publication number
ZA201107551B
ZA201107551B ZA2011/07551A ZA201107551A ZA201107551B ZA 201107551 B ZA201107551 B ZA 201107551B ZA 2011/07551 A ZA2011/07551 A ZA 2011/07551A ZA 201107551 A ZA201107551 A ZA 201107551A ZA 201107551 B ZA201107551 B ZA 201107551B
Authority
ZA
South Africa
Prior art keywords
compositions
methods
complement protein
antibodies targeting
targeting complement
Prior art date
Application number
ZA2011/07551A
Other languages
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Yong-In Kim
Ingo Klagge
Alexandra Kraus
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201107551B publication Critical patent/ZA201107551B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2011/07551A 2009-05-06 2011-10-14 Compositions and methods for antibodies targeting complement protein c3b ZA201107551B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06
PCT/EP2010/056129 WO2010136311A2 (en) 2009-05-06 2010-05-05 Compositions and methods for antibodies targeting complement protein c3b

Publications (1)

Publication Number Publication Date
ZA201107551B true ZA201107551B (en) 2012-07-25

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/07551A ZA201107551B (en) 2009-05-06 2011-10-14 Compositions and methods for antibodies targeting complement protein c3b

Country Status (22)

Country Link
US (1) US20100291106A1 (enExample)
EP (1) EP2427491A2 (enExample)
JP (1) JP2012525829A (enExample)
KR (1) KR20120088551A (enExample)
CN (1) CN102459334A (enExample)
AR (1) AR076655A1 (enExample)
AU (1) AU2010252156A1 (enExample)
CA (1) CA2760757A1 (enExample)
CL (1) CL2011002756A1 (enExample)
CO (1) CO6440515A2 (enExample)
EA (1) EA201101593A1 (enExample)
EC (1) ECSP11011445A (enExample)
IL (1) IL216061A0 (enExample)
MA (1) MA33402B1 (enExample)
MX (1) MX2011011754A (enExample)
PE (1) PE20120899A1 (enExample)
SG (1) SG175432A1 (enExample)
TN (1) TN2011000528A1 (enExample)
TW (1) TW201043638A (enExample)
UY (1) UY32612A (enExample)
WO (1) WO2010136311A2 (enExample)
ZA (1) ZA201107551B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
NZ600393A (en) 2009-11-05 2014-08-29 Alexion Cambridge Corp Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
AU2011336702B2 (en) * 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
CA2869477C (en) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
KR20150088853A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 c에 대한 인간화 모노클로날 항체 및 그의 용도
US20160051673A1 (en) 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
KR101834469B1 (ko) 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CA2926812A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
SG11201606983SA (en) * 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2018075474A1 (en) 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating central nervous system injury
TWI833742B (zh) * 2018-04-03 2024-03-01 美商恩格姆生物製藥公司 Ｃ３結合劑及其使用方法
EP3801772A1 (en) * 2018-06-11 2021-04-14 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US20240336683A1 (en) * 2021-03-19 2024-10-10 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
AU2022420788A1 (en) 2021-12-22 2024-05-16 Boehringer Ingelheim International Gmbh Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
AU2023347940A1 (en) * 2022-09-20 2025-03-27 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b-antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
KR20150139636A (ko) * 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
KR20150029002A (ko) * 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares

Also Published As

Publication number Publication date
TW201043638A (en) 2010-12-16
AU2010252156A1 (en) 2011-11-10
CA2760757A1 (en) 2010-12-02
IL216061A0 (en) 2012-01-31
WO2010136311A2 (en) 2010-12-02
CN102459334A (zh) 2012-05-16
UY32612A (es) 2010-12-31
KR20120088551A (ko) 2012-08-08
CL2011002756A1 (es) 2012-03-23
US20100291106A1 (en) 2010-11-18
TN2011000528A1 (en) 2013-05-24
AR076655A1 (es) 2011-06-29
ECSP11011445A (es) 2012-01-31
JP2012525829A (ja) 2012-10-25
CO6440515A2 (es) 2012-05-15
EA201101593A1 (ru) 2012-06-29
EP2427491A2 (en) 2012-03-14
WO2010136311A3 (en) 2011-05-26
PE20120899A1 (es) 2012-08-03
MX2011011754A (es) 2011-11-29
SG175432A1 (en) 2011-12-29
MA33402B1 (fr) 2012-07-03

Similar Documents

Publication Publication Date Title
ZA201107551B (en) Compositions and methods for antibodies targeting complement protein c3b
IL300733B2 (en) Compositions and methods for antibodies and fusion proteins targeted for immune modulation
ZA201100375B (en) Compositions and methods for antibodies targeting complement protein c5
LT3178490T (lt) Rsv f baltymų kompozicijos ir jų gamybos būdai
IL218763A0 (en) Anti-gcc antibody molecules and related compositions and methods
IL225954B (en) Anti-her3 antibodies and preparations
SG10201402265YA (en) Stabilized protein compositions
ZA201303957B (en) Melt-blended protein composition
ZA201108536B (en) Bispecific antigen binding proteins
IL212545A (en) Isolated antibodies that bind to 3tlr and their pharmaceutical preparations
EP2542589A4 (en) ANTIBODIES AND COMPOSITIONS ANTI-HER2
IL208445A0 (en) Compositions and methods for immunotherapy
IL219470A0 (en) Compositions containing fractalknie-binding proteins and uses thereof
EP2498750A4 (en) COMPOSITIONS AND METHODS FOR REINFORCING THE EYES
GB0816976D0 (en) Protein
ZA201109283B (en) Protein
IL208188A0 (en) Compositions comprising antibodies or antibody fragments
LT2797579T (lt) Kompozicija, apimanti anti-gliuteno antikūnus ir taninus
HK1163697A (en) Compositions and methods for antibodies targeting complement protein c3b
GB2462726B (en) Protein expression
GB0818627D0 (en) Protein
GB0810567D0 (en) Protein expression
GB0811893D0 (en) Protein expression
GB0902222D0 (en) Protein expression
GB0909384D0 (en) Protein